397 related articles for article (PubMed ID: 2449118)
41. Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5.
Papsidero LD; Croghan GA; Asirwatham J; Gaeta J; Abenoza P; Englander L; Valenzuela L
Am J Pathol; 1985 Dec; 121(3):451-4. PubMed ID: 2416221
[TBL] [Abstract][Full Text] [Related]
42. Ratio of polyclonal-monoclonal prostate-specific antigen levels. Discrimination of nodal status in prostate tumors that produce low marker levels.
Stephenson RA; Greskovich FJ; Fritsche HA; James BC
Urol Clin North Am; 1991 Aug; 18(3):467-71. PubMed ID: 1715103
[TBL] [Abstract][Full Text] [Related]
43. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
44. Detection of circulating adenocarcinoma-associated antigen in the sera of cancer patients with a monoclonal antibody.
Hinoda Y; Imai K; Endo T; Yamashita T; Yachi A
Jpn J Cancer Res; 1985 Dec; 76(12):1203-11. PubMed ID: 2419298
[TBL] [Abstract][Full Text] [Related]
45. Antigenic epitopes of three tumor-associated antigens of well-differentiated squamous cell carcinoma of the larynx for use in monitoring patients in specific active immunochemotherapy trials.
Hollinshead AC
Cancer Detect Prev; 1987; 10(3-4):153-8. PubMed ID: 2436778
[TBL] [Abstract][Full Text] [Related]
46. [The role of monoclonal antibodies to the epithelial membrane antigen in the diagnosis of human tumors].
Delektorskaia VV; Ermilova VD; Baryshnikov AIu; Raĭkhlin NT
Vopr Onkol; 1992; 38(5):562-71. PubMed ID: 1300755
[TBL] [Abstract][Full Text] [Related]
47. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
[TBL] [Abstract][Full Text] [Related]
49. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants.
Krizan Z; Murray JL; Hersh EM; Rosenblum MG; Glenn HJ; Gschwind CR; Carlo DJ
Cancer Res; 1985 Oct; 45(10):4904-9. PubMed ID: 2411391
[TBL] [Abstract][Full Text] [Related]
50. Localization of a normal prostatic secretory product using the monoclonal antibody KR-P8.
Raynor RH; Mohanakumar T; Moncure CW; Hazra TA
J Urol; 1985 Aug; 134(2):384-7. PubMed ID: 2410635
[TBL] [Abstract][Full Text] [Related]
51. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
52. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
53. Search for oncogenic viruses in human prostate cancer.
Dmochowski L; Ohtsuki Y; Seman G; Maruyama K; Knesek JE; East JL; Bowen JM; Yoshida H; Johnson DE
Cancer Treat Rep; 1977; 61(2):119-27. PubMed ID: 68817
[TBL] [Abstract][Full Text] [Related]
54. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients.
Rochon YP; Horoszewicz JS; Boynton AL; Holmes EH; Barren RJ; Erickson SJ; Kenny GM; Murphy GP
Prostate; 1994 Oct; 25(4):219-23. PubMed ID: 8084837
[TBL] [Abstract][Full Text] [Related]
55. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms.
Nadji M; Tabei SZ; Castro A; Chu TM; Murphy GP; Wang MC; Morales AR
Cancer; 1981 Sep; 48(5):1229-32. PubMed ID: 6168364
[TBL] [Abstract][Full Text] [Related]
56. The detection of basal cell determinants in human basal cell carcinomas using two different monoclonal antibodies.
Habets JM; Tank B; Vuzevski VD; van Reede EC; Stolz E; van Joost T
Acta Derm Venereol; 1987; 67(5):391-8. PubMed ID: 2448989
[TBL] [Abstract][Full Text] [Related]
57. [Development and characterization of a monoclonal antibody which recognizes a new prostate-organ specific antigen].
Ka S; Eto H; Arakawa S; Kamidono S
Nihon Hinyokika Gakkai Zasshi; 1999 Sep; 90(9):790-7. PubMed ID: 10517088
[TBL] [Abstract][Full Text] [Related]
58. Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants.
Herlyn M; Shen JW; Sears HF; Civin CI; Verrill HL; Goldberg EM; Koprowski H
Clin Exp Immunol; 1984 Jan; 55(1):23-35. PubMed ID: 6198117
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal antibody (F5) to human prostate antigen.
Papsidero LD; Croghan GA; Wang MC; Kuriyama M; Johnson EA; Valenzuela LA; Chu TM
Hybridoma; 1983; 2(2):139-47. PubMed ID: 6205972
[TBL] [Abstract][Full Text] [Related]
60. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.
Troyer JK; Beckett ML; Wright GL
Prostate; 1997 Mar; 30(4):232-42. PubMed ID: 9111600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
